Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

Volumn , Issue , 2015, Pages 114-121

  Tan, David S P ^a   Kaye, Stanley B ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM;

DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BRCA2 PROTEIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROGNOSIS; TREATMENT OUTCOME;

EID: 85003050006     PISSN: None     EISSN: 15488756     Source Type: Journal    
DOI: 10.14694/EdBook_AM.2015.35.114     Document Type: Review

References (0)